Twist Bioscience Corporation (NASDAQ:TWST) Shares Purchased by New York State Common Retirement Fund

New York State Common Retirement Fund increased its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 2.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 452,750 shares of the company's stock after acquiring an additional 10,761 shares during the quarter. New York State Common Retirement Fund owned approximately 0.76% of Twist Bioscience worth $17,775,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Versant Capital Management Inc raised its holdings in shares of Twist Bioscience by 547.2% during the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after purchasing an additional 580 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Twist Bioscience by 68.1% during the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after purchasing an additional 303 shares during the last quarter. Banque Transatlantique SA bought a new position in shares of Twist Bioscience in the fourth quarter worth about $43,000. GF Fund Management CO. LTD. acquired a new stake in shares of Twist Bioscience during the 4th quarter worth approximately $58,000. Finally, Pallas Capital Advisors LLC acquired a new stake in shares of Twist Bioscience during the 1st quarter worth approximately $201,000.

Analyst Upgrades and Downgrades

TWST has been the subject of several research analyst reports. JPMorgan Chase & Co. reduced their price target on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Barclays dropped their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. Robert W. Baird lowered their price target on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. The Goldman Sachs Group decreased their target price on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Finally, Guggenheim reissued a "buy" rating and issued a $50.00 target price on shares of Twist Bioscience in a report on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Twist Bioscience currently has a consensus rating of "Moderate Buy" and a consensus target price of $50.40.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST traded down $0.68 during mid-day trading on Friday, reaching $35.17. 624,000 shares of the company traded hands, compared to its average volume of 965,940. The firm has a market cap of $2.11 billion, a PE ratio of -10.82 and a beta of 2.41. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.51 and a quick ratio of 4.24. Twist Bioscience Corporation has a 52 week low of $27.12 and a 52 week high of $60.90. The company's 50 day moving average price is $33.69 and its 200-day moving average price is $39.46.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 54.98% and a negative return on equity of 33.48%. The company had revenue of $92.79 million for the quarter, compared to analysts' expectations of $92.00 million. On average, equities analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, CFO Adam Laponis sold 2,449 shares of the business's stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total transaction of $93,429.35. Following the transaction, the chief financial officer owned 103,569 shares of the company's stock, valued at approximately $3,951,157.35. The trade was a 2.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Dennis Cho sold 689 shares of the business's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $37.65, for a total value of $25,940.85. Following the completion of the sale, the insider owned 110,849 shares in the company, valued at $4,173,464.85. This represents a 0.62% decrease in their position. The disclosure for this sale can be found here. Insiders sold 24,961 shares of company stock valued at $877,006 in the last 90 days. 3.01% of the stock is currently owned by corporate insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.